The FDA approved oveporexton today, the first drug that works by switching on the brain's orexin system — the wakefulness signal that is missing in people with narcolepsy type 1, a condition affecting an estimated 120,000 Americans. The approval rests on two randomized, placebo-controlled trials of 273 adults over twelve weeks. On a standard test of staying awake, patients on the higher dose lasted about nineteen minutes longer than those on placebo, from a baseline under five; daytime sleepiness scores fell by nearly ten points; cataplexy attacks dropped by about two-thirds. The harms are in the same tables: insomnia in 55–60% of treated patients against 1% on placebo, frequent urination in more than half, and a muscle-enzyme signal the label will carry. We write about a narcolepsy drug on a longevity site for one reason. This is what evidence for a sleep product looks like, and nothing sold to you for sleep has ever had to produce it.
Compare the paperwork. Mouth tape: ten small studies, 213 people, mostly no benefit, a review warning of asphyxiation risk. Melatonin: a supplement with no trial required and a database study last fall associating long-term use with worse heart outcomes. Sleep-tracking rings and bands: no trial required, no outcome claimed. Oveporexton: two randomized trials, a validated primary endpoint, every side effect counted and published before a single prescription. The drug is for a rare, serious disease and almost no reader of this site will ever take it. The standard it met is the one to hold against everything else in the aisle.
Loree’s takeNarcolepsy type 1 is the clearest case in sleep medicine: a specific missing signal, a drug that supplies it, a trial that measures the thing patients care about. Most of my patients' sleep problems are not like that. They are late bedtimes, screens, alcohol, worry and untreated apnea, and the treatment is behavioral and free. But when someone tells me a sleep product works, I now have a comparison: did it show what this drug showed? Almost nothing does.
Ben’s takeThe orexin story started in 1998 with a peptide nobody expected to matter for sleep, ran through mice, dogs and spinal-fluid samples, and arrived at a pharmacy twenty-eight years later. That is the pace of real sleep science. The sleep-products industry runs on a different clock — a video, a launch, a subscription — and its customers subsidize the difference between the two. Today one side of that ledger published its evidence. The other side never will.
Why it matters to a recovering optimizer. The sleep fundamental is mostly behavior, and the evidence for behavior — regular hours, enough of them, less alcohol, treated apnea — is strong and costs nothing. Where a drug is needed, today shows what earning that word requires. Where a product is sold instead, ask for the two trials. If there are none, you are not buying sleep; you are buying a story about it.
For any sleep product, ask: randomized trial, validated endpoint, harms counted? If not, it is a story, not a treatment.
This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.